Search
Enliven Therapeutics Inc
ELVNAdd to Watchlist
48.950USD
-1.800-3.55%
Market hours （ET）Quotes delayed by 15 min
2.98BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated:Analyst Rating
Based on
12
analysts
Buy
Current Rating
62.100
Target Price
+22.12%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
561
Total
5
Median
6
Average
Company name
Ratings
Analysts
Enliven Therapeutics Inc
ELVN
12
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Enliven Therapeutics Inc's price target?
Analysts forecast that Enliven Therapeutics Inc's price target is USD 38.00, with the highest forecast at USD 52.00 and the lowest forecast at USD 33.00.
How have Enliven Therapeutics IncELVN's recent earnings per share performed?
The market expectation was USD -0.38, while Enliven Therapeutics IncELVN's earnings per share (EPS) for the previous quarter was USD -0.48. EPS for the next quarter is expected at USD -0.41.
What is the analyst rating for Enliven Therapeutics Inc?
Based on the ratings of Enliven Therapeutics Inc's stock from 12 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.